Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA In Twilight: Gov’t Shutdown Has Not Slowed Rx Operations Too Visibly Yet

Executive Summary

Shutdown puts API shipments on a slow boat, but reviews of existing products can proceed with carry-over funds, even as new applications cannot be filed. CDC has largely halted its influenza program and NIH has ceased enrolling new patients in its clinical center.

You may also be interested in...



US FDA Enters Shutdown Mode: Reviews Will Continue, But Will Morale?

User fee funding will allow many functions to continue, but only 58% of staff will be retained until funding deal is reached.

FDA's Government Shutdown Plan Ready, Just In Case

With a little more than a week left for Congress to extend government funding, US FDA and HHS plan for furloughs should no new appropriations be enacted.

FDA Shutdown Hangover Hurts Biosimilars, May Benefit Some ANDAs

As normal operations – and normal budget worries – resume, the agency has some meetings to reschedule.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS055644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel